Winship Cancer Institute of Emory University | Strategic Alliance Partners

Adding the mTOR inhibitor everolimus to conventional therapy slowed the progression of trastuzumab-resistant advanced breast cancer, and in the process, provided clues to the origin of trastuzumab resistance.

Suresh S. Ramalingam, MD, from the Winship Cancer Institute of Emory University, discusses the role of heat shock proteins in normal cells and their potential role in treating cancer.

Suresh S. Ramalingam, MD, from Emory University's Winship Cancer Institute, explains that a number of new cytotoxic drugs are being developed in combination with targeted therapies, such as EGFR inhibitors.

David Schuster, MD, director, from Emory University, compares the efficacy of bone scans and FDG-PET/CT scans for detecting bone metastases in patients with breast cancer.

The level of C-reactive protein (CRP) expressed in the tumor specimens of patients with renal cell carcinoma (RCC) may serve as a widely available biomarker for postoperative prognosis of localized disease.